Skip to main content
. 2017 Sep 14;7:11625. doi: 10.1038/s41598-017-10414-x

Table 3.

Age and 5-year DFS, 5-year DMFS and 5-years BCSS by Molecular Subtype.

Subtype/Age (years) Patients N(%) 5-year DFS, N(%) HR (95%CI)* 5-year DRFS, N(%) HR (95%CI)* 5-year BCSS, N(%) HR (95%CI)*
Luminal A
≤40 112 85 (75.9) 2.06 (1.15 to 3.69) 87 (77.7) 1.88 (1.04 to 3.41) 104 (92.9) 5.85 (1.22 to 28.0)
 41–50 183 161 (69.4) 1.00 (REF) 161 (88.0) 1.00 (REF) 181 (98.9) 1.00 (REF)
 51–60 100 81 (81.0) 1.61 (0.86 to 3.03) 82 (82.0) 1.53 (0.81 to 2.91) 96 (96.0) 3.56 (0.65 to 19.5)
>60 71 55 (77.5) 1.94 (0.90 to 4.20) 55 (77.5) 1.96 (0.90 to 4.27) 66 (93.0) 5.02 (0.82 to 30.95)
Luminal B Her-2 (−)
≤40 186 112 (60.2) 1.47 (1.05 to 2.06) 117 (62.9) 1.51 (1.06 to 2.15) 168 (90.3) 1.73 (0.87 to 3.44)
 41–50 232 161 (69.4) 1.00 (REF) 166 (71.6) 1.00 (REF) 216 (93.1) 1.00 (REF)
 51–60 168 116 (69.0) 1.12 (0.77 to 1.63) 122 (72.6) 1.09 (0.74 to 1.62) 147 (87.5) 2.24 (1.12 to 4.49)
>60 86 59 (68.6) 0.87 (0.54 to 1.41) 59 (65.1) 0.96 (0.59 to 1.56) 78 (90.7) 1.41 (0.58 to 3.44)
Luminal B Her-2 (+)
≤40 107 52 (48.6) 1.00 (0.63 to 1.58) 53 (51.0) 1.11 (0.69 to 1.79) 76 (71.0) 0.80 (0.40 to 1.59)
 41–50 114 70 (61.4) 1.00 (REF) 75 (65.8) 1.00 (REF) 92 (80.7) 1.0 (REF)
 51–60 72 40 (55.6) 1.10 (0.67 to 1.81) 43 (59.7) 1.11 (0.65 to 1.89) 55 (76.4) 1.04 (0.52 to 2.09)
>60 24 14 (58.3) 0.93 (0.44 to 1.99) 15 (62.5) 0.94 (0.42 to 2.08) 19 (79.2) 0.90 (0.31 to 2.59)
HER-2 over-expression
≤40 70 38 (54.3) 1.27 (0.79 to 2.05) 41 (58.6) 1.23 (0.74 to 2.04) 47 (67.1) 1.73 (0.91 to 3.31)
 41–50 114 74 (64.9) 1.00 (REF) 77 (67.5) 1.00 (REF) 96 (84.2) 1.00 (REF)
 51–60 127 80 (63.0) 0.98 (0.63 to 1.53) 82 (64.6) 0.99 (0.63 to 1.57) 94 (74.0) 1.07 (0.55 to 2.08)
>60 36 21 (58.3) 0.85 (0.42 to 1.70) 21 (58.3) 0.92 (0.45 to 1.88) 31 (86.1) 0.75 (0.24 to 2.29)
Triple negative
≤40 82 52 (63.4) 1.44 (0.86 to 2.40) 54 (65.9) 1.33(0.78 to 2.24) 65 (79.3) 1.13 (0.59 to 2.17)
41–50 116 85 (73.3) 1.00 (REF) 86 (74.1) 1.00 (REF) 94 (81.0) 1.00 (REF)
51–60 88 64 (72.7) 0.87 (0.50 to 1.52) 65 (73.9) 0.90 (0.51 to 1.58) 75 (85.2) 0.73 (0.36 to 1.50)
>60 52 28 (53.8) 2.16 (1.22 to 3.82) 30 (57.7) 1.94 (1.07 to 3.51) 37 (71.2) 1.94(0.98 to 3.86)

*Adjusted for tumor stage, histological grade, chemotherapy, endocrine-therapy, trastuzumab.